CLAIMS

1. A use of a riluzole prodrug in the manufacture of a medicament ~~method~~ for~~of~~ treating Alzheimer's Disease in a patient in need thereof, ~~comprising administering to the patient a therapeutically effective amount of~~ wherein said ~~a~~ riluzole prodrug has the following formula~~.~~



.

~~2. The method of claim 1, wherein the riluzole prodrug has the following formula:~~



~~and pharmaceutically acceptable salts thereof, wherein:~~

~~R_{23} is selected from the group consisting H, CH_3, CH_2CH_3, $CH_2CH_2CH_3$, CH_2CCH, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2OH, CH_2OCH_2Ph, $CH_2CH_2OCH_2Ph$, $CH(OH)CH_3$, CH_2Ph, CH_2(cyclohexyl), CH_2(4-OH-Ph), $(CH_2)_4NH_2$, $(CH_2)_3NHC(NH_2)NH$, CH_2(3-indole), CH_2(5-imidazole), CH_2CO_2H, $CH_2CH_2CO_2H$, CH_2CONH_2, and $CH_2CH_2CONH_2$.~~

~~3. The method of claim 2, wherein the riluzole prodrug has the following formula:~~



~~4~~2. The use~~method~~ of claim 1, wherein the riluzole prodrug is to be administered to the patient at a dosage of from ~~about~~ 100 to 400 mg per day.

~~5~~3. The use~~method~~ of claim ~~4~~2, wherein the riluzole prodrug is to be administered to the patient at a dosage of ~~about~~ 110, or 140, or 150, or 210, or 280, or 350 mg per day.

~~6~~4. The use~~method~~ of claim ~~5~~3, wherein the riluzole prodrug is to be administered to the patient at a dosage of 280 mg, once per day.

~~7~~5. The use~~method~~ of claim ~~6~~4, wherein the riluzole prodrug is to be administered to the patient at a dosage of 140 mg, twice per day.

~~8~~6. The use~~method~~ of claim 1, wherein the riluzole prodrug is to be administered to the patient once per day.

~~9~~7. The use~~method~~ of claim 1, wherein the riluzole prodrug is to be administered to the patient twice per day.

~~10~~8. The use~~method~~ of claim 1, wherein the riluzole prodrug is to be administered to the patient in the form of a capsule.

~~11~~9. The use~~method~~ of claim 1, wherein the riluzole prodrug is to be administered to the patient in the form of a tablet.

~~12~~10. The use~~method~~ of claim 1, wherein the riluzole prodrug is to be administered to the patient for a duration of from ~~about~~ 8 weeks to 48 weeks.

~~13~~11. The use~~method~~ of claim 1, wherein the riluzole prodrug is to be administered to the patient for a duration of from the onset of treatment to the end of the patient's life.

~~14~~12. A use of a riluzole prodrug in the manufacture of a medicament~~method~~ for improving a response in a patient afflicted with Alzheimer's disease, ~~comprising administering to the patient in need thereof, an effective amount of~~ wherein said ~~a~~ riluzole prodrug has the following formula



.

~~15~~13. The use~~method~~ of claim ~~14~~ 12 wherein the improved response is one or more of overall survival, quality of life, overall response rate, duration of response, delay of onset, or patient reported outcome.

~~16~~14. A kit for treating a patient afflicted with Alzheimer's Disease, the kit comprising:

(a) a riluzole prodrug having the formula



; and

(b) instructions for administering the riluzole prodrug in the ~~method~~ use of any of claims 1-~~15~~13.

~~17. The kit of claim 16 wherein the prodrug has the following formula:~~

